Table 3 Patient characteristics by EPPK1 expression levels in LUAD
From: Elucidating the role of EPPK1 in lung adenocarcinoma development
Characteristic | N | All LUAD1 (N = 140) | EPPK1 Low1 (N = 72) | EPPK1 High1 (N = 68) | P value2 |
|---|---|---|---|---|---|
Age | 140 | 67 (60–71.25) | 65 (59–71.25) | 67 (61–71.25) | 0.48 |
Gender | 140 | 0.02 | |||
Female | 78 (55.7%) | 47 (65.3%) | 31 (45.6%) | ||
Male | 62 (44.3%) | 25 (34.7%) | 37 (54.4%) | ||
Smoking history | 140 | 0.15 | |||
Ever | 117 (83.6%) | 57 (79.2%) | 60 (88.2%) | ||
Never | 23 (16.4%) | 15 (20.8%) | 8 (11.8%) | ||
Pack years | 136 | 40 (12.75–60) | 29 (10–55) | 45 (20–61) | 0.03 |
Performance Status | 136 | 15 (11.0%) | 6 (8.7%) | 9 (13.4%) | 0.38 |
Stage | 140 | 0.13 | |||
I | 79 (56.4%) | 47 (65.3%) | 32 (47.1%) | ||
II | 32 (22.9%) | 12 (16.7%) | 20 (29.4%) | ||
III | 24 (17.1%) | 10 (13.9%) | 14 (20.6%) | ||
IV | 5 (3.6%) | 3 (4.2%) | 2 (2.9%) | ||
COPD | 131 | 38 (29.0%) | 14 (20.6%) | 24 (38.1%) | 0.03 |
Gene alterations | 71 | ||||
KRAS | 47 (33.6%) | 24 (33.3%) | 23 (33.8%) | 0.95 | |
EGFR | 17 (12.1%) | 12 (16.7%) | 5 (7.4%) | 0.09 | |
BRAF | 3 (2.1%) | 2 (2.8%) | 1 (1.5%) | 0.99 | |
PIK3CA | 2 (1.4%) | 1 (1.4%) | 1 (1.5%) | 0.99 | |
MEK | 1 (0.7%) | 0 (0.0%) | 1 (1.5%) | 0.49 | |
ALK | 1 (0.7%) | 1 (1.4%) | 0 (0.0%) | 0.99 |